The San Diego-based company, backed by multiple blue-chip venture capital investors, focuses on developing ophthalmic pharmaceutical products to treat presbyopia, a condition that affects nearly two billion people worldwide and over 120 million people in the US. Their lead program is an aceclidine-based eye drop that restores near vision loss associated with presbyopia. Founded in 2013, LENZ Therapeutics offers patients a safe, on-demand, rapid-acting, and long-lasting pharmaceutical option to address their presbyopia symptoms.